The history of the erectile dysfunction drug presents a intricate picture for investors. While the initial introduction generated substantial profits, the lapse of its intellectual property protection opened the avenue to cheaper alternatives, dramatically eroding revenue. This creates a unique challenge for pharmaceutical companies depending on Ga

The history of Viagra, and its developer copyright, presents a intriguing case study for investors. Initially a blockbuster drug, generating billions in income, its patent expiration created a wave of lower-priced alternatives , significantly diminishing its dominance. While some pharmaceutical companies may seek to capitalize on similar conditions